Latest news with #HimanshuBakshi
Business Standard
6 days ago
- Business
- Business Standard
Sanofi Consumer Healthcare spurts after Q2 results
Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025. The company reported a 28% year-on-year rise in revenue to Rs 220.9 crore in Q2 2025, powered by export operations and successful product launches. On a sequential basis, the companys revenue rose 27.5% from Rs 172.6 crore in Q1 2025. Profit after tax (PAT) for the quarter stood at Rs 60.7 crore, marking a 21% increase over Q1FY25 and a 109% surge from Rs 29 crore in Q2 2024. Profit before tax (PBT) came in at Rs 78.9 crore, up 102.83% YoY and 18.11% QoQ. While result is impressive, the company noted that financials are not strictly comparable due to the demerger and voluntary recall of certain variants of key brands. Net cash flow from operations during the half year ended 30 June 2025 stood at Rs 17.9 crore, steeply down from Rs 231.50 crore in the same period last year. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said: "Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy-driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers." During the half year, the company launched Allegra D, a unique proposition in the Allergy segment, also relaunched Depura 60k and Combiflam Suspension which were recalled voluntarily last year. Other legacy brands such as Avil, and Depura continue to uphold strong consumer trust and drive long-term relevance in their respective categories. Sanofi Consumer Healthcare India officially demerged from Sanofi India on 1 June 2024 and now operates as an independent entity focused solely on the consumer healthcare segment. Its key product categories include allergy care, digestive wellness, pain relief, multivitamins, and herbal/traditional supplements, with flagship brands such as Allegra, DePURA, Avil, and Combiflam anchoring its portfolio.
Business Standard
03-05-2025
- Business
- Business Standard
Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr
Sanofi Consumer Healthcare India (SCHIL) reported a 20.25% year-on-year (YoY) decline in net profit to Rs 50 crore for the quarter ended 31 March 2025, compared to Rs 62.70 crore in the same period last year. Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy. SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofis global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra, DePURA, Avil, and Combiflam. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday.
